cx-4945 has been researched along with Leukemia--Lymphocytic--Chronic--B-Cell* in 2 studies
2 other study(ies) available for cx-4945 and Leukemia--Lymphocytic--Chronic--B-Cell
| Article | Year |
|---|---|
Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines | 2014 |
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine | 2013 |